BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38100141)

  • 1. The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis.
    Rodríguez-Tajes S; García-Eliz M; Marcos AC; Campos-Varela I; Ros AC; Loinaz C; Gómez Bravo MÁ; Rodríguez-Perálvarez M; Fabrega E; González Diéguez ML; Vinaixa C; Pascasio JM; Vázquez IF; Baliellas C; Castells L; Salcedo M; Prieto M; Crespo G; Lens S; Forns X
    Liver Int; 2024 Feb; 44(2):279-285. PubMed ID: 38100141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins.
    Lenci I; Tariciotti L; Angelico R; Milana M; Signorello A; Manzia TM; Toti L; Tisone G; Angelico M; Baiocchi L
    Clin Transplant; 2023 Jun; 37(6):e14971. PubMed ID: 36928864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplantation of hepatitis D virus patients: Lifelong hepatitis B immunoglobulins?
    Ferenci P; Reiberger T; Stadlbauer V; Zoller H
    Liver Int; 2023 Aug; 43 Suppl 1():96-100. PubMed ID: 35767373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
    Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
    Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation.
    Battistella S; Zanetto A; Gambato M; Germani G; Senzolo M; Burra P; Russo FP
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts.
    Orfanidou A; Papatheodoridis GV; Cholongitas E
    Liver Int; 2021 Jul; 41(7):1448-1461. PubMed ID: 33656809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.
    Cholongitas E; Papatheodoridis GV
    Am J Transplant; 2013 Feb; 13(2):353-62. PubMed ID: 23137006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients.
    Manini MA; Bruce M; Whitehouse G; Mazzarelli C; Considine A; Agarwal K; Suddle A; Fagiuoli S; Heaton N; Heneghan M
    Transplant Proc; 2021; 53(1):207-214. PubMed ID: 32605776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
    Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
    Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
    Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
    World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
    Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
    Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
    Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
    Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
    Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
    Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
    Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
    Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
    Manini MA; Whitehouse G; Bruce M; Passerini M; Lim TY; Carey I; Considine A; Lampertico P; Suddle A; Heaton N; Heneghan M; Agarwal K
    Dig Liver Dis; 2018 Sep; 50(9):944-953. PubMed ID: 29735294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database.
    Park GC; Hwang S; Kim MS; Jung DH; Song GW; Lee KW; Kim JM; Lee JG; Ryu JH; Choi DL; Wang HJ; Kim BW; Kim DS; Nah YW; You YK; Kang KJ; Yu HC; Park YH; Lee KJ; Kim YK
    J Korean Med Sci; 2020 Feb; 35(6):e36. PubMed ID: 32056398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.